Immunotherapy has fundamentally transformed the treatment landscape in cancer.

In the placebo-controlled phase 3 PACIFIC trial, the programmed cell death-ligand 1 inhibitor durvalumab demonstrated significant improvements in survival in patients with unresectable, stage III non-small lung cancer.

This has led to the widespread acceptance of the ‘PACIFIC regimen’ (durvalumab after chemoradiotherapy) as the standard of care in this setting.

As durvalumab is the first immunotherapy with a proven survival advantage in a curative-intent setting, there is a strong rationale for its further investigation in early-stage cancers.

An extensive clinical development program, as described herein, is investigating durvalumab across multiple tumor types in curative-intent settings.